Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
G1 Therapeutics, Inc. (GTHX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/02/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
06/16/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
06/09/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "EXHIBIT 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH"
05/03/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/03/2023 8-K Quarterly results
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/01/2023 10-K Annual Report for the period ended December 31, 2022
03/01/2023 8-K Quarterly results
02/13/2023 8-K Quarterly results
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 3.8% stake in G1 Therapeutics Inc.
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023 8-K Investor presentation
Docs: "41st Annual J.P. Morgan Healthcare Conference Wednesday January 11, 1:30 PM PT Advancing"
12/06/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/18/2022 8-K Quarterly results
11/18/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/17/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/02/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 8-K Quarterly results
08/03/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights - Achieved $8.7 Million in Net Revenue from Sales of COSELA® in the Second Quarter of 2022 and $10.6 Million in Total Revenue -"
07/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors"
07/11/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/28/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/24/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/04/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/04/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy